Next Article in Journal
Dissolution Advantage of Nitazoxanide Cocrystals in the Presence of Cellulosic Polymers
Next Article in Special Issue
Influence of Composition and Spray-Drying Process Parameters on Carrier-Free DPI Properties and Behaviors in the Lung: A review
Previous Article in Journal
Polysaccharides in Ocular Drug Delivery
Previous Article in Special Issue
An Inhalable Theranostic System for Local Tuberculosis Treatment Containing an Isoniazid Loaded Metal Organic Framework Fe-MIL-101-NH2—From Raw MOF to Drug Delivery System
Open AccessArticle

Dispersibility and Storage Stability Optimization of High Dose Isoniazid Dry Powder Inhalation Formulations with L-Leucine or Trileucine

Department of Pharmaceutical Technology and Biopharmacy, Faculty of Science and Engineering, University of Groningen, 9700 AB Groningen, The Netherlands
*
Author to whom correspondence should be addressed.
Pharmaceutics 2020, 12(1), 24; https://doi.org/10.3390/pharmaceutics12010024
Received: 26 October 2019 / Revised: 6 December 2019 / Accepted: 18 December 2019 / Published: 25 December 2019
(This article belongs to the Special Issue Advances in Pulmonary Drug Delivery)
Tuberculosis is the leading cause of death from a single infectious pathogen worldwide. Lately, the targeted delivery of antibiotics to the lungs via inhalation has received increasing interest. In a previous article, we reported on the development of a spray-dried dry powder isoniazid formulation containing an L-leucine coating. It dispersed well but had poor physical stability. In this study, we aimed to improve the stability by improving the leucine coating. To this end, we optimized the spray-drying conditions, the excipient content, and the excipient itself. Using L-leucine, the tested excipient contents (up to 5%) did not result in a stable powder. Contrary to L-leucine, the stability attained with trileucine was satisfactory. Even when exposed to 75% relative humidity, the formulation was stable for at least three months. The optimal formulation contained 3% trileucine w/w. This formulation resulted in a maximum fine particle dose of 58.00 ± 2.56 mg when a nominal dose of 80 mg was dispersed from the Cyclops® dry powder inhaler. The improved moisture protection and dispersibility obtained with trileucine are explained by its amorphous nature and a higher surface enrichment during drying. Dispersion efficiency of the device decreases at higher nominal doses. View Full-Text
Keywords: high dose pulmonary delivery; dry powder inhaler; drug formulation; inhalation; tuberculosis high dose pulmonary delivery; dry powder inhaler; drug formulation; inhalation; tuberculosis
Show Figures

Figure 1

MDPI and ACS Style

Sibum, I.; Hagedoorn, P.; Kluitman, M.P.G.; Kloezen, M.; Frijlink, H.W.; Grasmeijer, F. Dispersibility and Storage Stability Optimization of High Dose Isoniazid Dry Powder Inhalation Formulations with L-Leucine or Trileucine. Pharmaceutics 2020, 12, 24.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop